| HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression … RK Gupta, J Gregson, N Parkin, H Haile-Selassie, A Tanuri, LA Forero, ... The Lancet infectious diseases 18 (3), 346-355, 2018 | 440 | 2018 |
| Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low-and middle-income countries: a systematic review and meta-analysis TS Boender, KCE Sigaloff, JH McMahon, S Kiertiburanakul, MR Jordan, ... Clinical Infectious Diseases 61 (9), 1453-1461, 2015 | 181 | 2015 |
| Viral suppression after 12 months of antiretroviral therapy in low-and middle-income countries: a systematic review JH McMahon, JH Elliott, S Bertagnolio, R Kubiak, MR Jordan Bulletin of the World Health Organization 91, 377-385, 2013 | 167 | 2013 |
| World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites MR Jordan, DE Bennett, S Bertagnolio, CF Gilks, D Sutherland Antiviral therapy 13 (2_suppl), 15-23, 2008 | 160 | 2008 |
| Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform … S Bertagnolio, SS Thwin, R Silva, S Nagarajan, W Jassat, R Fowler, ... The Lancet HIV 9 (7), e486-e495, 2022 | 136 | 2022 |
| The WHO public health approach to HIV treatment and care: looking back and looking ahead N Ford, A Ball, R Baggaley, M Vitoria, D Low-Beer, M Penazzato, ... The Lancet Infectious Diseases 18 (3), e76-e86, 2018 | 135 | 2018 |
| Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub–Saharan Africa AN Phillips, J Stover, V Cambiano, F Nakagawa, MR Jordan, D Pillay, ... The Journal of infectious diseases 215 (9), 1362-1365, 2017 | 134 | 2017 |
| Suboptimal viral suppression rates among HIV-infected children in low-and middle-income countries: a meta-analysis RS Boerma, TS Boender, AP Bussink, JCJ Calis, S Bertagnolio, ... Clinical infectious diseases, ciw645, 2016 | 134 | 2016 |
| Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study AN Phillips, F Venter, D Havlir, A Pozniak, D Kuritzkes, A Wensing, ... The lancet HIV 6 (2), e116-e127, 2019 | 127 | 2019 |
| Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology E Tacconelli, M Tumbarello, S Bertagnolio, R Citton, T Spanu, G Fadda, ... Emerging infectious diseases 8 (2), 220, 2002 | 126 | 2002 |
| Clinical Management of COVID‐19 JV Diaz, A Baller, A Bannerjee, S Bertagnolio Geneva, Switzerland: World Health Organization, 2020 | 125 | 2020 |
| Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance. S Bertagnolio, NT Parkin, M Jordan, J Brooks, JG García-Lerma AIDS reviews 12 (4), 195-208, 2010 | 120 | 2010 |
| Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis BJ Langford, JPR Soucy, V Leung, M So, ATH Kwan, JS Portnoff, ... Clinical Microbiology and Infection 29 (3), 302-309, 2023 | 118 | 2023 |
| HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, R Kantor, GU Van Zyl, ... PloS one 10 (12), e0145772, 2015 | 105 | 2015 |
| Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis BJ Langford, M So, M Simeonova, V Leung, J Lo, T Kan, S Raybardhan, ... The Lancet Microbe 4 (3), e179-e191, 2023 | 103 | 2023 |
| Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active anti retroviral therapy M Tumbarello, R Rabagliati, K de Gaetano Donati, S Bertagnolio, ... BMC infectious diseases 4, 1-11, 2004 | 95 | 2004 |
| Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis L Kuhn, G Hunt, KG Technau, A Coovadia, J Ledwaba, S Pickerill, ... Aids 28 (11), 1673-1678, 2014 | 93 | 2014 |
| Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings V Cambiano, S Bertagnolio, MR Jordan, JD Lundgren, A Phillips The Journal of infectious diseases 207 (suppl_2), S57-S62, 2013 | 92 | 2013 |
| HIV-1 drug resistance surveillance using dried whole blood spots S Bertagnolio, L Soto-Ramirez, R Pilon, R Rodriguez, M Viveros, ... Antiviral therapy 12 (1), 107-114, 2007 | 90 | 2007 |
| Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within … NI Paton, C Kityo, J Thompson, I Nankya, L Bagenda, A Hoppe, J Hakim, ... The lancet HIV 4 (8), e341-e348, 2017 | 82 | 2017 |
